Intensive frontline therapy in MCL
| Phase . | Induction . | Consolidation . | N . | OR (CR) (%) . | Median response . | Median OS . | TRM . | Reference . |
|---|---|---|---|---|---|---|---|---|
| II (single center) | R-HyperCVAD | — | 97 | 97 (87) | 48% 8 yr FFS | 56% 8 yr | 8% | 18 |
| II (multicenter) | R-HyperCVAD | — | 60 | 83 (72) | 61% 5 yr PFS | 73% 5 yr | 6.5% | 20 |
| II (multicenter) | R-HyperCVAD | — | 49 | 86 (55) | 4.8 yr PFS | 6.8 yr | 2% | 21 |
| III (randomized) | R-CHOP | Dexa BEAM ASCT | 455 | 98 (63) | 3.8 yr PFS | 6.8 yr | 4% | 24 |
| vs | vs | vs | vs | |||||
| R-CHOP/R-DHAP | ASCT | 99 (61) | 7.3 yr PFS | NR | ||||
| III (randomized) | CHOP | Interferon | 122 | 99 (37) | 1.4 yr PFS | 77% 3 yr | 0% | 76 |
| or | vs | |||||||
| R-CHOP | ASCT | 98 (81) | 3.3 yr PFS | 83% 3 yr | 5% | |||
| II (multicenter) | R-Maxi-CHOP + HD AraC | ASCT | 160 | 96 (54) | 7.4 yr EFS | 70% 6 yr | 5% | 22 |
| II (multicenter) | R-CHOP / R-DHAP | ASCT | 60 | 82 (78) | 7 yr EFS | 75% 5 yr | 1.50% | 77 |
| II (multicenter) | R-CHOP + MTX + HD AraC + etoposide | ASCT | 77 | 88 (69) | 56% 5 yr PFS | 64% 5 yr | 3% | 78 |
| II (multicenter) | R-CHOP + HD AraC | ASCT | 87 | 70 (64) | 36% 4 yr PFS | 66% 4 yr | 5% | 79 |
| Phase . | Induction . | Consolidation . | N . | OR (CR) (%) . | Median response . | Median OS . | TRM . | Reference . |
|---|---|---|---|---|---|---|---|---|
| II (single center) | R-HyperCVAD | — | 97 | 97 (87) | 48% 8 yr FFS | 56% 8 yr | 8% | 18 |
| II (multicenter) | R-HyperCVAD | — | 60 | 83 (72) | 61% 5 yr PFS | 73% 5 yr | 6.5% | 20 |
| II (multicenter) | R-HyperCVAD | — | 49 | 86 (55) | 4.8 yr PFS | 6.8 yr | 2% | 21 |
| III (randomized) | R-CHOP | Dexa BEAM ASCT | 455 | 98 (63) | 3.8 yr PFS | 6.8 yr | 4% | 24 |
| vs | vs | vs | vs | |||||
| R-CHOP/R-DHAP | ASCT | 99 (61) | 7.3 yr PFS | NR | ||||
| III (randomized) | CHOP | Interferon | 122 | 99 (37) | 1.4 yr PFS | 77% 3 yr | 0% | 76 |
| or | vs | |||||||
| R-CHOP | ASCT | 98 (81) | 3.3 yr PFS | 83% 3 yr | 5% | |||
| II (multicenter) | R-Maxi-CHOP + HD AraC | ASCT | 160 | 96 (54) | 7.4 yr EFS | 70% 6 yr | 5% | 22 |
| II (multicenter) | R-CHOP / R-DHAP | ASCT | 60 | 82 (78) | 7 yr EFS | 75% 5 yr | 1.50% | 77 |
| II (multicenter) | R-CHOP + MTX + HD AraC + etoposide | ASCT | 77 | 88 (69) | 56% 5 yr PFS | 64% 5 yr | 3% | 78 |
| II (multicenter) | R-CHOP + HD AraC | ASCT | 87 | 70 (64) | 36% 4 yr PFS | 66% 4 yr | 5% | 79 |
ASCT, autologous stem cell transplant; BEAM, BCNU, etoposide, cytarabine, melphalan; CHOP, cyclophosphamide, doxorubicin, vincristine, and prednisolone; CR, complete remission; FFS, failure-free survival; HD-AraC, high-dose cytarabine; MTX, methotrexate; N, number of patients; NR, not reached; OR, overall response; OS, overall survival; R-CHOP, rituximab plus CHOP; R-DHAP, rituximab, dexamethasone, cytarabine, and cisplatin; R-HyperCVAD, rituximab plus fractionated cyclophosphamide, vincristine, and doxorubicin; TRM, treatment-related mortality.